Newsroom

Through multiple G-Rex® Grants, ScaleReady and Children’s National Hospital are collaborating to advance pediatric CAR-T, VST, and TAAT programs—demonstrating how partnership and innovation can redefine the future of cell therapy manufacturing for young patients worldwide.

Eight California CIRM network institutions received nearly $2 million in G-Rex® Grants from ScaleReady, recognizing G-Rex® as the foundation for scalable, standardized cell therapy production—and the only proven path to meeting global patient demand.

The Translational Sciences Laboratory at the Gates Institute will use a $300,000 grant from ScaleReady to leverage the G-Rex® platform in developing a modular, high-throughput CAR-T manufacturing system for next-generation cell therapies.

Sidra Medicine in Qatar has been awarded a $100,000 ﹙USD﹚ G‑Rex® Grant from ScaleReady to develop a CD19 CAR-T cell platform for pediatric oncology, including technology transfer and GMP-compliant manufacturing set-up.

University of Minnesota’s researchers received $665,000 via G‑Rex® Grants from ScaleReady to power development of a CAR-NK therapy for ovarian cancer, TIL therapy for solid tumors, and T-cell treatment for Batten Disease.

Akadeum’s instrument-free microbubble process highlights the versatility of ScaleReady’s G-Rex® platform, demonstrating how partners are designing innovative, scalable workflows that build on its proven foundation for efficient and flexible cell therapy manufacturing.

The $150K G-Rex® Grant supports Immuneel’s shift to more efficient, scalable CAR-T cell manufacturing in India. This collaboration aims to accelerate access to life-saving cell therapies by reducing production complexity and cost.

ScaleReady and its partners have awarded four G-Rex® Grants totaling over $1M to leading researchers at USC and CHLA to accelerate innovative CAR-T and T cell therapy programs targeting solid tumors and pediatric cancers.

A2 Biotherapeutics receives a $300,000 G-Rex® Grant to support scalable CAR-T manufacturing and process development using its Tmod™ platform for solid tumor therapies.

March Biosciences has been awarded a $200,000 G-Rex® Grant from ScaleReady and partners to streamline cGMP manufacturing of its MB-105 CAR-T therapy for CD5-positive T-cell lymphomas.

Josh Ludwig - Global Commercial Director at ScaleReady talks to IBTV about G-Rex, open collaboration and ScaleReady's current projects at Phacilitate's - Advanced Therapies Week at the Kay Bailey Hutchison Convention Center, Dallas, Texas, 20 – 23 January 2025.

Learn how BrainChild Bio is accelerating its groundbreaking CAR-T therapy for pediatric brain cancer with a $300,000 G-Rex® Grant supported by ScaleReady and its partners.